Xencor | XNCR - Ordinary Share Capital


Xencor reported $71.3M in Ordinary Share Capital for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 879.42M
Cash and Equivalent USD 44.44M
Cost of Sales USD 61.66M
Current Assets USD 513.15M
Current Liabilities USD 96.08M
Debt USD 67.93M
EBIT USD -22.83M
EBITDA USD -30.52M
Employees 250
EPS Earnings Per Share USD -0.41
Equity Capital and Reserves USD 620.35M
Gross Profit on Sales USD 43.61M
Interest Expense on Debt USD 8.24M
Interest Income USD 7.25M
Loan Capital USD 94.74M
Market Capitalization USD 522.6M
Net Income USD -30.83M
Operating Expenses USD 76.78M
Operating Profit USD -33.17M
Ordinary Share Capital USD 71.3M
PE Price to Earnings USD 29.92
Pre-Tax Profit USD -31.08M
Sales Revenues USD 43.61M
Selling and Administration Expenses USD 15.12M
Stock USD 0
Trade Creditors USD 18.53M
Trade Debtors USD 47.55M

Ordinary Share Capital Change Date
AbbVie USD 18M 0 Dec/2024
Alnylam Pharmaceuticals USD 130.98M 129.67M Jun/2025
Amgen USD 538M 33.04B Jun/2025
Arrowhead Research USD 138.14M 137.91M Jun/2025
AstraZeneca USD 1.55B 1.16B Jun/2025
Biogen USD 146.6M 146.5M Jun/2025
Bristol-Myers Squibb USD 2.04B 1.74B Jun/2025
Cytokinetics USD 119.6M 119.48M Jun/2025
GlaxoSmithKline GBP 4.15B 2.8B Jun/2025
J&J USD 3.12B 0 Mar/2025
MacroGenics USD 63.21M 62.58M Jun/2025
Merck USD 1.79B 0 Mar/2025
Novartis USD 793M 0 Dec/2024
Pfizer USD 5.68B 5.2B Jun/2025
Regeneron Pharmaceuticals USD 106.4M 106.4M Jun/2025
Roche Holding CHF 107M 0 Jun/2024
Xencor USD 71.3M 70.58M Jun/2025